Introduction to Molecular Vision
Molecular Vision is an R&D stage in vitro diagnostic company that has developed a technology platform that could radically change how diagnostic tests are administered to patients. The low-cost, instrument-free, disposable point-of-care (PoC) device is able to measure previously incompatible parameters on a single test from a single sample, providing both quantitative and qualitative information.
A spinout of Imperial College London, the Company leverages its expertise in optical detection to measure the light signal change associated with one or several optical parameters in biological assays on its BioLEDTM technology platform. To date, Molecular Vision has validated the flexibility of the platform by multiplexing an albumin and creatinine panel in a urine sample as well as a Myoglobin and CK-MB panel in a serum sample; each panel respectively, on an integrated microfluidic device.
Molecular Vision's prototype fluorescence devices offer sub nanomolar sensitivities in a portable low-cost format. Absorbance and chemiluminescence based detection platforms are currently under development.
London, UK, 24 January 2012
Molecular Vision featured in latest issue of Wired magazine
Molecular Vision Limited (“Molecular Vision” or “the Company”), a spin-out of Imperial College active in the commercialisation of a novel disposable, quantitative electronic point of care diagnostic system, announces that its technology has been featured in the January 2012 issue of Wired magazine covering "25 big ideas for 2012".